成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

ChemicalBook >> journal list >> Frontiers in Pharmacology >>article
Frontiers in Pharmacology

Frontiers in Pharmacology

IF: 4.4
Download PDF

Palmitoylethanolamide (PEA) as a Potential Therapeutic Agent in Alzheimer’s Disease

Published:24 July 2019 DOI: 10.3389/fphar.2019.00821
S. Beggiato,?M. C. Tomasini,?L. Ferraro

Abstract

N-Palmitoylethanolamide (PEA) is a non-endocannabinoid lipid mediator belonging to the class of the N-acylethanolamine phospolipids and was firstly isolated from soy lecithin, egg yolk, and peanut meal. Either preclinical or clinical studies indicate that PEA is potentially useful in a wide range of therapeutic areas, including eczema, pain, and neurodegeneration. PEA-containing products are already licensed for use in humans as a nutraceutical, a food supplement, or a food for medical purposes, depending on the country. PEA is especially used in humans for its analgesic and anti-inflammatory properties and has demonstrated high safety and tolerability. Several preclinical in vitro and in vivo studies have proven that PEA can induce its biological effects by acting on several molecular targets in both central and peripheral nervous systems. These multiple mechanisms of action clearly differentiate PEA from classic anti-inflammatory drugs and are attributed to the compound that has quite unique anti(neuro)inflammatory properties. According to this view, preclinical studies indicate that PEA, especially in micronized or ultramicronized forms (i.e., formulations that maximize PEA bioavailability and efficacy), could be a potential therapeutic agent for the effective treatment of different pathologies characterized by neurodegeneration, (neuro)inflammation, and pain. In particular, the potential neuroprotective effects of PEA have been demonstrated in several experimental models of Alzheimer’s disease. Interestingly, a single-photon emission computed tomography (SPECT) case study reported that a mild cognitive impairment (MCI) patient, treated for 9?months with ultramicronized-PEA/luteolin, presented an improvement of cognitive performances. In the present review, we summarized the current preclinical and clinical evidence of PEA as a possible therapeutic agent in Alzheimer’s disease. The possible PEA neuroprotective mechanism(s) of action is also described.

Substances (2)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Luteolin 491-70-3 C15H10O6 606 suppliers $5.00-$1250.00
Palmitoylethanolamide 544-31-0 C18H37NO2 353 suppliers $21.00-$891.38

Similar articles

IF:3.7

A Synopsis of Multitarget Potential Therapeutic Effects of Huperzine A in Diverse Pathologies–Emphasis on Alzheimer’s Disease Pathogenesis

Neurochemical Research Mayuri Shukla, Prapimpun Wongchitrat,etc Published: 5 February 2022
IF:3.5

Naringenin: A prospective therapeutic agent for Alzheimer's and Parkinson's disease

Journal of Food Biochemistry Ahsas Goyal, Aanchal Verma,etc Published: 15 September 2022
IF:6.7

Phytochemicals: A potential next generation agent for radioprotection

Phytomedicine Bimal Prasad Jit , Subhaswaraj Pattnaik ,etc Published: 1 November 2022